- Our Company
- News & Events
- Contact Us
On 16 July 2019, Guardant Health AMEA and GC Genome announced their collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea. The Guardant360® Launch Symposium, held at the Grand Intercontinental Seoul Parnas, aimed to address the growing cancer burden in South Korea which has risen to over 277,000 new cancer cases and close to 87,000 cancer deaths in 2019 according to the International Agency for Research on Cancer.
The launch symposium was well attended by over 80 South Korean oncologists and physicians and led by Guardant Health and GC Genome medical officers who shared their insightful perspectives about the benefits of comprehensive genomic profiling through a plenary session and panel discussion.